Caribou Biosciences, Inc.

NASDAQ:CRBU

Biotechnology

Healthcare
$0.49 -2.74%

-$0.05 today

Market cap
$52.47M
Beta
2.33
P/E (TTM)
-1.1
EPS (TTM)
-$1.39
52W Low $1.20High $3.54

Volume 1.01M

Average 1.83M

Returns on capital

Caribou Biosciences, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-121.2%

avg -60.8%

ROIC

-89.8%

avg -59.2%

ROA

-84.5%

avg -47.2%

Analysis

ROA is currently the strongest return metric at -84.5% versus its period average of -47.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Rachel E. Haurwitz

Co-Founder, Chief Executive Officer, President & DirectorUSD 993.61K40447.15K0.45%

Timothy Kelly

Chief Technology OfficerUSD 730.05K56——

Barbara G. McClung

Chief Legal Officer & Corporate SecretaryUSD 686.72K71481.56K0.49%

Tina Albertson

Chief Medical OfficerUSD 677.08K52——

Sriram Ryali

Chief Financial OfficerUSD 663.51K4472.36K0.07%

Ruhi A. Khan

Chief Business OfficerUSD 573.9K50——

Jennifer A. Doudna

Co-founder & Member of Scientific Advisory Board—62——

Ryan Fischesser

Interim Principal Accounting Officer & Controller——118.85K0.12%

Reigin Zawadzki

Chief People Officer————

Compensation is shown in the reported currency; data updated Oct 3, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Feb 24, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

5

$47,474.48

Net Transaction Value

−$47,474.48

Net selling

Most Active

Kelly Timothy P

2 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Feb 25, 26

Kelly Timothy P

Direct

Sell$12K
Feb 24, 26

Albertson Tina M.

Direct

Sell$2.1K
Feb 24, 26

Kelly Timothy P

Direct

Sell$6.2K
Feb 24, 26

MCCLUNG BARBARA G

Direct

Sell$13.6K
Feb 24, 26

Khan Ruhi Ahmad

Direct

Sell$13.6K

Summary

Insiders reported 0 buys worth $0.00 and 5 sells worth $47,474.48 over the last 12 months. That adds up to net selling of $47,474.48. Kelly Timothy P was the most active insider with 2 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A-7.0%
+53.5% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at -7.0% over three years. Forward estimates point to Revenue at +53.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Caribou Biosciences, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about CRBU's management, answered from reported figures.

Who manages CRBU?

Caribou Biosciences, Inc. (CRBU) lists 9 active executives. The top listed executive is Barbara G. McClung, Chief Legal Officer & Corporate Secretary.

Are CRBU insiders buying or selling?

Recent insider activity shows net buying of $52.30M.